Community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is now the leading cause of superficial abscesses seen in the Emergency Department.
Our primary aim was to determine if an association exists between three predictor variables (abscess size, cellulitis size, and MRSA culture) and treatment failure within 7 days after incision and drainage in adults. Our secondary aim was to determine if an association exists between two clinical features (abscess size and size of surrounding cellulitis) and eventual MRSA diagnosis by culture.
Logistic regression models were used to examine clinical variables as predictors of treatment failure within 7 days after incision and drainage and MRSA by wound culture.
Of 212 study participants, 190 patients were analyzed and 22 were lost to follow-up. Patients who grew MRSA, compared to those who did not, were more likely to fail treatment (31% to 10%, respectively; 95% confidence interval [CI] 8–31%). The failure rates for abscesses ≥ 5 cm and < 5 cm were 26% and 22%, respectively (95% CI −11–26%). The failure rates for cellulitis ≥ 5 cm and < 5 cm were 27% and 16%, respectively (95% CI −2–22%). Larger abscesses were no more likely to grow MRSA than smaller abscesses (55% vs. 53%, respectively; 95% CI −22–23%). The patients with larger-diameter cellulitis demonstrated a slightly higher rate of MRSA-positive culture results compared to patients with smaller-diameter cellulitis (61% vs. 46%, respectively; 95% CI −0.3–30%), but the difference was not statistically significant.
Cellulitis and abscess size do not predict treatment failures within 7 days, nor do they predict which patients will have MRSA. MRSA-positive patients are more likely to fail treatment within 7 days of incision and drainage.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Emergency Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections.Ann Emerg Med. 2005; 45: 311-320
- Methicillin resistant S. aureus infections among patients in the emergency department.N Engl J Med. 2006; 355: 666-674
- Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection.Ann Emerg Med. 2010; 56: 283-287
- Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient.Ann Emerg Med. 2010; 55: 401-407
- Randomized, double blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for methicillin resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2007; 5: 4044-4048
- Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.Pediatr Infect Dis J. 2004; 23: 123-127
- Risk factors for methicillin-resistant Staphylococcal aureus skin and soft tissue infections presenting in primary care: a South Texas Ambulatory Research Network (STARNet) Study.J Am Board Fam Med. 2009; 22: 375-379
- Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation.Clin Infect Dis. 2007; 44: 471-482
- Clinical importance of purulence in methicillin-resistant Staphylococcus aureus skin and soft tissue infections.J Am Board Fam Med. 2009; 22: 647-654
- Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department.CJEM. 2009; 11: 430-438
- Emergency department physician ability to predict methicillin-resistant Staphyloccus aureus skin and soft tissue infections.J Emerg Med. 2010; 39: 17-20
- Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.Pharmacotherapy. 2005; 25: 253-264
- Diagnostic and therapeutic evaluation of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections in the emergency department.J Emerg Med. 2012; 42: 392-399
Published online: June 14, 2012
Accepted: September 27, 2011
Received in revised form: June 8, 2011
Received: November 1, 2010
This article does not reflect the views of Brooke Army Medical Center, the United States Army, the Department of Defense, or the Federal Government.
Published by Elsevier Inc.